CN103529225A - 一种肝型脂肪酸结合蛋白含量检测试剂盒及其制备方法 - Google Patents
一种肝型脂肪酸结合蛋白含量检测试剂盒及其制备方法 Download PDFInfo
- Publication number
- CN103529225A CN103529225A CN201310539830.7A CN201310539830A CN103529225A CN 103529225 A CN103529225 A CN 103529225A CN 201310539830 A CN201310539830 A CN 201310539830A CN 103529225 A CN103529225 A CN 103529225A
- Authority
- CN
- China
- Prior art keywords
- fatty acid
- binding protein
- acid binding
- reagent
- type fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 238000001514 detection method Methods 0.000 title abstract description 57
- 102000030914 Fatty Acid-Binding Human genes 0.000 title abstract description 15
- 108091022862 fatty acid binding Proteins 0.000 title abstract description 15
- 239000002245 particle Substances 0.000 claims abstract description 133
- 239000004816 latex Substances 0.000 claims abstract description 127
- 229920000126 latex Polymers 0.000 claims abstract description 127
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000004094 surface-active agent Substances 0.000 claims abstract description 20
- 239000000375 suspending agent Substances 0.000 claims abstract description 12
- 239000007853 buffer solution Substances 0.000 claims abstract description 5
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 claims description 95
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 claims description 95
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 claims description 95
- 239000004005 microsphere Substances 0.000 claims description 79
- 239000000243 solution Substances 0.000 claims description 79
- 238000013016 damping Methods 0.000 claims description 44
- 239000012530 fluid Substances 0.000 claims description 44
- 238000006243 chemical reaction Methods 0.000 claims description 32
- 239000012153 distilled water Substances 0.000 claims description 29
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 25
- 239000004793 Polystyrene Substances 0.000 claims description 25
- 229920002223 polystyrene Polymers 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 17
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 16
- 230000002421 anti-septic effect Effects 0.000 claims description 16
- 230000021523 carboxylation Effects 0.000 claims description 15
- 238000006473 carboxylation reaction Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 11
- 239000008363 phosphate buffer Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 10
- 239000006172 buffering agent Substances 0.000 claims description 10
- 238000010790 dilution Methods 0.000 claims description 10
- 239000012895 dilution Substances 0.000 claims description 10
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- -1 antiseptic Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- HVUMOYIDDBPOLL-UHFFFAOYSA-N 2-(3,4-Dihydroxyoxolan-2-yl)-2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)C1OCC(O)C1O HVUMOYIDDBPOLL-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 3
- YHSHAHLOHLZILM-UHFFFAOYSA-L S(=S)(=O)([O-])[O-].[Na+].C(C)[Hg].[Na+] Chemical compound S(=S)(=O)([O-])[O-].[Na+].C(C)[Hg].[Na+] YHSHAHLOHLZILM-UHFFFAOYSA-L 0.000 claims description 3
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 3
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 3
- 229940101027 polysorbate 40 Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 3
- 229940033663 thimerosal Drugs 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 239000003755 preservative agent Substances 0.000 abstract description 3
- 230000002335 preservative effect Effects 0.000 abstract description 3
- 238000011002 quantification Methods 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 229910019142 PO4 Inorganic materials 0.000 description 20
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 20
- 239000010452 phosphate Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 12
- 238000004321 preservation Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- 229960002449 glycine Drugs 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000002331 protein detection Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 150000001718 carbodiimides Chemical class 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical group CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310539830.7A CN103529225B (zh) | 2013-11-04 | 2013-11-04 | 一种肝型脂肪酸结合蛋白含量检测试剂盒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310539830.7A CN103529225B (zh) | 2013-11-04 | 2013-11-04 | 一种肝型脂肪酸结合蛋白含量检测试剂盒及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103529225A true CN103529225A (zh) | 2014-01-22 |
CN103529225B CN103529225B (zh) | 2016-01-13 |
Family
ID=49931402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310539830.7A Active CN103529225B (zh) | 2013-11-04 | 2013-11-04 | 一种肝型脂肪酸结合蛋白含量检测试剂盒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103529225B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103954775A (zh) * | 2014-05-12 | 2014-07-30 | 国家纳米科学中心 | 一种检测生物大分子或微生物体的方法 |
CN105785036A (zh) * | 2016-03-29 | 2016-07-20 | 四川大学华西医院 | 一种肺癌筛查试剂盒 |
CN112858696A (zh) * | 2021-02-24 | 2021-05-28 | 江西英大生物技术有限公司 | 肝素结合蛋白测定试剂盒 |
CN115684108A (zh) * | 2022-10-18 | 2023-02-03 | 中生北控生物科技股份有限公司 | 一种检测肌钙蛋白i的试剂盒及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006299417A1 (en) * | 2005-10-03 | 2007-04-12 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes |
WO2009040400A1 (en) * | 2007-09-28 | 2009-04-02 | Roche Diagnostics Gmbh | Means and methods for the detection of contrast medium-induced nephrotoxicity |
WO2011007823A1 (ja) * | 2009-07-15 | 2011-01-20 | 国立大学法人東京大学 | 敗血症又は多臓器不全の予後診断方法及び予後診断用キット |
CN102998468A (zh) * | 2012-09-20 | 2013-03-27 | 武汉华美生物工程有限公司 | 25-羟基维生素d3检测试剂盒及其制备方法和应用 |
CN103123319A (zh) * | 2012-12-20 | 2013-05-29 | 武汉生之源生物科技有限公司 | 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法 |
CN103175964A (zh) * | 2013-02-21 | 2013-06-26 | 武汉华美生物工程有限公司 | 神经元特异性烯醇化酶含量检测试剂盒及其制备方法 |
CN103308681A (zh) * | 2013-06-25 | 2013-09-18 | 武汉生之源生物科技有限公司 | 胰蛋白酶原-2检测试剂盒及制备方法 |
CN103323596A (zh) * | 2012-10-31 | 2013-09-25 | 武汉生之源生物科技有限公司 | 髓过氧化物酶含量检测试剂盒及其制备方法 |
-
2013
- 2013-11-04 CN CN201310539830.7A patent/CN103529225B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006299417A1 (en) * | 2005-10-03 | 2007-04-12 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes |
WO2009040400A1 (en) * | 2007-09-28 | 2009-04-02 | Roche Diagnostics Gmbh | Means and methods for the detection of contrast medium-induced nephrotoxicity |
WO2011007823A1 (ja) * | 2009-07-15 | 2011-01-20 | 国立大学法人東京大学 | 敗血症又は多臓器不全の予後診断方法及び予後診断用キット |
CN102998468A (zh) * | 2012-09-20 | 2013-03-27 | 武汉华美生物工程有限公司 | 25-羟基维生素d3检测试剂盒及其制备方法和应用 |
CN103323596A (zh) * | 2012-10-31 | 2013-09-25 | 武汉生之源生物科技有限公司 | 髓过氧化物酶含量检测试剂盒及其制备方法 |
CN103123319A (zh) * | 2012-12-20 | 2013-05-29 | 武汉生之源生物科技有限公司 | 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法 |
CN103175964A (zh) * | 2013-02-21 | 2013-06-26 | 武汉华美生物工程有限公司 | 神经元特异性烯醇化酶含量检测试剂盒及其制备方法 |
CN103308681A (zh) * | 2013-06-25 | 2013-09-18 | 武汉生之源生物科技有限公司 | 胰蛋白酶原-2检测试剂盒及制备方法 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103954775A (zh) * | 2014-05-12 | 2014-07-30 | 国家纳米科学中心 | 一种检测生物大分子或微生物体的方法 |
CN103954775B (zh) * | 2014-05-12 | 2015-08-19 | 国家纳米科学中心 | 一种检测生物大分子或微生物体的方法 |
CN105785036A (zh) * | 2016-03-29 | 2016-07-20 | 四川大学华西医院 | 一种肺癌筛查试剂盒 |
CN105785036B (zh) * | 2016-03-29 | 2018-06-26 | 四川大学华西医院 | 一种肺癌筛查试剂盒 |
CN112858696A (zh) * | 2021-02-24 | 2021-05-28 | 江西英大生物技术有限公司 | 肝素结合蛋白测定试剂盒 |
CN112858696B (zh) * | 2021-02-24 | 2022-02-01 | 江西英大生物技术有限公司 | 肝素结合蛋白测定试剂盒 |
CN115684108A (zh) * | 2022-10-18 | 2023-02-03 | 中生北控生物科技股份有限公司 | 一种检测肌钙蛋白i的试剂盒及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103529225B (zh) | 2016-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102759631B (zh) | 一种定量检测降钙素原pct的胶乳增强免疫比浊试剂盒 | |
CN102662061B (zh) | 胶乳增强免疫比浊法测定人甲胎蛋白含量的试剂盒 | |
WO2016127318A1 (zh) | 心肌肌钙蛋白i超敏检测试剂盒及其超敏检测方法 | |
CN109596843B (zh) | 一种血清淀粉样蛋白a的测定试剂盒 | |
CN103792353B (zh) | 一种脂蛋白相关磷脂酶a2含量检测试剂盒及其制备方法 | |
CN101699287B (zh) | 匀相溶胶颗粒型胱抑素c测定试剂盒及其制备方法 | |
CN109085333A (zh) | 一种类风湿因子抗原的制备、检测试剂盒及制备方法 | |
CN106932589A (zh) | 测定人体血清视黄醇结合蛋白含量的试剂盒及其制备方法 | |
CN103048464A (zh) | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒及其制备方法 | |
CN102590497A (zh) | 胱氨酸蛋白酶抑制剂c检测试剂盒 | |
CN108152512A (zh) | 肝素结合蛋白检测试剂盒及其制备方法 | |
CN103529225B (zh) | 一种肝型脂肪酸结合蛋白含量检测试剂盒及其制备方法 | |
CN102662064A (zh) | 检测中性粒细胞明胶酶相关脂质运载蛋白的免疫比浊试剂盒及其制备方法 | |
CN103454431A (zh) | 检测β2微球蛋白的免疫比浊试剂盒及其制备方法 | |
CN104569434A (zh) | 高尔基体蛋白gp73乳胶增强免疫比浊检测试剂盒及其制备方法 | |
CN104614528A (zh) | 一种线性范围更宽的视黄醇结合蛋白测定试剂盒 | |
CN106918708A (zh) | 一种用于检测胰岛素的竞争法胶乳增强免疫透射比浊试剂盒 | |
CN110007074A (zh) | 用于检测c反应蛋白的试剂盒、其制备方法及用途 | |
CN103954766B (zh) | 转铁蛋白受体检测试剂盒及制备方法 | |
CN108051439A (zh) | 一种单试剂肝素结合蛋白检测试剂盒及其制备方法 | |
CN107589266A (zh) | 一种血管内皮生长因子胶乳增强免疫比浊试剂盒及其应用 | |
CN108872616B (zh) | 基于单粒径胶乳颗粒的检测ngal的免疫胶乳比浊法试剂盒 | |
CN202916286U (zh) | 一种定量检测降钙素原pct的胶乳增强免疫比浊试剂盒 | |
CN105699665A (zh) | 一种中性粒细胞明胶酶相关脂质运载蛋白的检测试剂盒 | |
CN103308681A (zh) | 胰蛋白酶原-2检测试剂盒及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Liver fatty acid binding protein content detection kit and preparation method thereof Effective date of registration: 20181227 Granted publication date: 20160113 Pledgee: Wuhan rural commercial bank Limited by Share Ltd Optics Valley branch Pledgor: CUSABIO Biotech Co., Ltd. Registration number: 2018420000079 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201228 Granted publication date: 20160113 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: CUSABIO BIOTECH Co.,Ltd. Registration number: 2018420000079 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A liver type fatty acid binding protein content detection kit and its preparation method Effective date of registration: 20210128 Granted publication date: 20160113 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: CUSABIO BIOTECH Co.,Ltd. Registration number: Y2021420000005 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210601 Granted publication date: 20160113 Pledgee: Guanggu Branch of Wuhan Rural Commercial Bank Co.,Ltd. Pledgor: CUSABIO BIOTECH Co.,Ltd. Registration number: Y2021420000005 |